82070-01-7

Basic information

• Product Name: 6-FLUOROCHROMAN
• Synonyms: 6-FLUOROCHROMAN;6-Fluoro-3,4-dihydro-2H-1-benzopyran;6-fluoro-3,4-dihydro-2H-chroMene;2H-1-BENZOPYRAN, 6-FLUORO-3,4-DIHYDRO
• CAS NO: 82070-01-7
• Molecular Formula: C₉H₉FO
• Molecular Weight: 152.17
• Product Categories: Aromatics, Heterocycles, Impurities, Pharmaceuticals, Intermediates & Fine Chemicals
• Mol File: 82070-01-7.mol
• Article Data: 5

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 6-FLUOROCHROMAN(CAS DataBase Reference)
• NIST Chemistry Reference: 6-FLUOROCHROMAN(82070-01-7)
• EPA Substance Registry System: 6-FLUOROCHROMAN(82070-01-7)

Safety Data

• Hazardous Substances Data: 82070-01-7(Hazardous Substances Data)

Usage

Uses

6-Fluorochroman is an impurity of Nebivolol (N387900), a β1-adrenergic blocker used as an antihypertensive agent.

Upstream product

• 1579-78-8 3-(4-fluoro-phenoxy)propionic acid 
• 66892-34-0 6-fluoro-4-chromanone 

Downstream Products

• 1421435-11-1 2-[2-(6-fluorochroman-4-ylidene)hydrazinyl]-5-phenylthiazole 
• 188826-25-7 6-fluoro-8-hydroxychroman 

Relevant articles and documents

Synthesis and antifungal activity of some thiazole derivatives

A series of some thiazole derivatives were designed and synthesized. The structure of newly synthesized compounds was characterized by HRMS, 1H NMR and 13C NMR. The synthesized compounds were evaluated against ten species of fungi in vitro by agar cup plate and micro-titration methods, respectively. The results of antifungal screening reveal that among all the compounds screened three compounds showed moderate antifungal activity. The MIC value of 3 h against two fungal strains C. neoformans and C. albicas is 8 μg mL-1 respectively. The MIC value of 3i against two fungal strains C. neoformans and T. mentagrophytes is 8 μg mL-1 and 16 μg mL-1, respectively and 3a against T. mentagrophytes is 16 μg mL-1, the MIC of others are all beyond 32 μg mL-1.

ARYLPIPERAZINYL-CYCLOHEXYL INDOLE DERIVATIVES FOR THE TREATMENT OF DEPRESSION

Compounds are provided which are useful for the treatment of serotonin-affected neurological disorders which comprise (I) wherein: Ra, R1, R2 and R3 are each, independently, hydrogen, or a substituent selected from halogen, CF3, alkyl, alkoxy, MeSO2, amino or aminocarbonyl (each optionally substituted by one or two groups selected from alkyl and benzyl) carboxy, or alkoxycarbonyl; or two adjacent of Ra and R1-4 together can form a 5-7 membered carbocyclic or heterocyclic ring which is optionally substituted by a substituent defined above; R4 is hydrogen, halogen, or alkyl; R5 is hydrogen, alkyl, arylalkyl, or aryl; R6 is hydrogen, halogen, CF3, CN, carbamide, alkoxy or benzyloxy; X1, X2 and X3 are each carbon or one of X1, X2 or X3 may be nitrogen; Y is CH or nitrogen; and Z is carbon or nitrogen; or pharmaceutically acceptable salts thereof.

Hypoglycemic 5-substituted oxazolidine-2,4-diones

Hypoglycemic 5-chromanyl, 2,3-dihydro-5-benzo[b]furanyl, 5-pyridyl, 5-quinolyl, 5-pyrrolyl, 5-indolyl, 5-thiazolyl, 5-oxazolyl, 5-isothiazolyl and 5-isoxazolyl oxazolidine-2,4-diones and the pharmaceutically acceptable salts thereof; certain 3-acylated derivatives thereof; a method of treating hyperglycemic animals therewith; and intermediates useful in the preparation of said compounds.